The E2F1 transcription factor, which is deregulated in most human cancers by mutations in the p16-cyclin D-Rb pathway, has both oncogenic and tumor-suppressive properties. This is dramatically illustrated by the phenotype of an E2F1 transgenic mouse model that spontaneously develops tumors in the skin and other epithelial tissues but is resistant to papilloma formation when subjected to a two-stage carcinogenesis protocol. Here, this E2F1 transgenic model was used to further explore the tumor-suppressive property of E2F1. Transgenic expression of E2F1 was found to inhibit ras-driven skin carcinogenesis at the promotion stage independent of the type of promoting agent used. E2F1 transgenic epidermis displayed increased expression of p19 ARF , p53, and p21
Introduction
Although E2F genes are rarely mutated in human tumors, there is much evidence to suggest that deregulation of E2F-dependent transcriptional control is a key event in the development of most cancers. This is supported by the finding that several members of the E2F family can behave as oncogenes in cell culture and in transgenic mice (Johnson et al., 1994a; Xu et al., 1995; Pierce et al., 1998b Pierce et al., , 1999 Conner et al., 2000) . The oncogenic capacity of some E2F family members is thought to be related to their ability to regulate the expression of numerous genes involved in cell cycle progression and DNA replication. Overexpression of several components of E2F activity, including E2F1, can transcriptionally activate such genes and induce entry into the S phase of the cell cycle (Johnson et al., 1993; DeGregori et al., 1997) .
Surprisingly, some of the same E2F genes that demonstrate oncogenic activity also demonstrate tumorsuppressive properties. Mice lacking either E2F1 or E2F2 are predisposed to developing spontaneous tumors, including hematopoietic malignancies, reproductive tract sarcomas, and adenomas of the lung (Yamasaki et al., 1996; Zhu et al., 2001 ). E2F1's ability to suppress tumorigenesis is further illustrated by the acceleration of spontaneous tumorigenesis seen in K5 Myc transgenic mice when they are crossed into an E2f1 null background .
One possible mechanism to explain E2F1's tumorsuppressive property is its ability to promote apoptosis when overexpressed or deregulated by Rb inactivation (Wu and Levine, 1994; DeGregori et al., 1997; Pan et al., 1998; Tsai et al., 1998) . E2F1-mediated apoptosis has been associated with the transcriptional upregulation of a number of target genes including multiple members of the caspase family and Apaf1 (Moroni et al., 2001; Nahle et al., 2002) . Moreover, transcriptional activation of the p73 and PKR genes by E2F1 has been associated with the ability of E2F1 to induce p53-independent apoptosis in a number of human cancer cell lines (Irwin et al., 2000; Vorburger et al., 2002) . However, in normal human and primary mouse fibroblast cultures, E2F1-induced apoptosis is p53-dependent (Qin et al., 1994; Wu and Levine, 1994; Kowalik et al., 1995) . In addition, the p53-dependent apoptosis resulting from Rb inactivation in both Rb À/À embryos and SV40 transgenic mice requires E2F1 (Pan et al., 1998; Tsai et al., 1998) .
It has been proposed that E2F1 activates p53 to induce apoptosis through the transcriptional activation of the ARF tumor suppressor, a positive regulator of p53. Like p53, the ARF gene is frequently mutated in human cancers. Mice lacking ARF are prone to spontaneous tumor development with very early onset, most commonly lymphomas and sarcomas, underscoring its role as a potent tumor suppressor (Kamijo et al., 1997) . ARF modifies various p53-dependent signaling pathways by inhibiting mdm2 (de Stanchina et al., 1998; Palmero et al., 1998; Zindy et al., 1998; Khan et al., 2000) , which functions to counteract p53 by blocking its transcriptional activity, promoting its translocation to the cytoplasm, and targeting it for degradation by the proteasome (Prives, 1998; Sherr, 2000) . Thus, maintenance of p53 at low levels is achieved by a transcriptional negative-feedback loop between p53 and mdm2, which ARF disrupts to activate p53 (Barak et al., 1993; Wu et al., 1993; Prives, 1998; Sherr, 2000) .
The idea that ARF is involved in E2F1-induced apoptosis is based on the finding that the ARF promoter contains an E2F DNA-binding site and overexpression of E2F1 transcriptionally activates ARF (DeGregori et al., 1997; Bates et al., 1998) . Moreover, p53-dependent apoptosis induced by Myc, another oncogenic transcription factor, requires ARF Russell et al., 2002) . However, there have been a number of reports contrary to the widely accepted model that ARF mediates p53-dependent apoptosis induced by E2F1. Tsai et al. (2002) have demonstrated that ARF is not necessary for the tissue-specific apoptosis in Rb À/À embryos that requires p53 and E2F1. ARF-independence was also reported in a model system utilizing a truncated SV40 T-antigen to inactivate Rb leading to p53-and E2F1-dependent apoptosis (Tolbert et al., 2002) . We found that not only was ARF not required for E2F1-induced apoptosis in a transgenic mouse model but also that ARF appeared to function as a negative regulator of E2F1-induced apoptosis and proliferation (Russell et al., 2002) . We and others also found that ARF was dispensable for apoptosis induced by E2F1 overexpression in primary mouse fibroblast cultures (Rogoff et al., 2002; Russell et al., 2002) . Subsequent studies have revealed that E2F1 overexpression induces p53 phosphorylation and apoptosis via the ATM/NBS1/Chk2 pathway (Powers et al., 2004; Rogoff et al., 2004) .
In addition to promoting apoptosis under some circumstances, ARF and p53 can also induce a transient cell cycle arrest or a permanent arrest with features of senescence (Kamijo et al., 1997; Serrano et al., 1997; Lin et al., 1998; Lin and Lowe, 2001; Wei et al., 2001) . This later process is often referred to as premature or stressinduced senescence to differentiate it from replicative senescence, which is associated with the loss of telomeres. Although the overexpression of E2F1 is usually associated with the stimulation of proliferation and apoptosis, Campisi and co-workers have demonstrated that overexpression of E2F1 in normal human fibroblasts induces a senescent-like state (Dimri et al., 2000) . The induction of premature senescence by E2F1 was associated with an increase in ARF expression and the accumulation of p53. Moreover, E2F1-induced senescence was abrogated by the inactivation of either p53 or ARF (Dimri et al., 2000) .
Our lab has generated transgenic mice that overexpress E2F1 under the control of the bovine keratin 5 (K5) promoter to study the role of deregulated E2F1 in tumor development (Pierce et al., 1998a) . The K5 promoter targets transgene expression to the basal layer of the epidermis and several other epithelial tissues (Ramirez et al., 1994) . K5 E2F1 transgenic mice exhibit epidermal hyperproliferation and increased apoptosis that is dependent on p53 but not ARF (Pierce et al., 1998a, b; Russell et al., 2002) . Although K5 E2F1 transgenic mice develop spontaneous tumors in the skin and some other K5-expressing tissues after 1 year of age, they are resistant to tumor development when used in a two-stage skin carcinogenesis assay (Pierce et al., 1999) . This two-stage carcinogenesis assay uses a single dose of the carcinogen 7,12-dimethylbenz[a]anthracene (DMBA) as the initiating agent, which results in an activating mutation at codon 61 of the c-Ha-ras gene (Quintanilla et al., 1986) . Tumor development is then promoted by repeated applications of 12-O-tetradecanoylphorbol-13-acetate (TPA), which results in hyperplasia and the outgrowth of benign papillomas. A subset of the benign papillomas can then progress to malignant squamous cell carcinomas. The ability to suppress tumor development in this model system is unique to E2F1 since the transgenic expression of other E2F family members, such as E2F3, E2F4 or DP1, or of Myc does not inhibit two-stage carcinogenesis but actually enhances it (Wang et al., 2000 (Wang et al., , 2001 Rounbehler et al., 2001) .
In this report, K5 E2F1 transgenic mice were subjected to different variations of the original twostage skin carcinogenesis assay to explore the mechanism involved in tumor suppression by E2F1 in this model system. E2F1 was found to suppress skin tumor formation at the promotion stage and this was not specific to the type of tumor promoter used but was specific for the initiation event. In ARF-or p53-deficient backgrounds, K5 E2F1 transgenic mice were susceptible to two-stage carcinogenesis. Thus, an intact ARF-p53 pathway is required for E2F1 to inhibit tumorigenesis in this model.
Results
Suppression of skin carcinogenesis in K5 E2F1 transgenic mice occurs at the promotion stage and is not specific to TPA K5 E2F1 transgenic mice are resistant to papilloma formation in two-stage carcinogenesis experiments using DMBA as the initiator and TPA as the promoter (Pierce et al., 1999) . To determine if E2F1 overexpression inhibits skin carcinogenesis at the initiation or promotion stage, the Tg.AC transgenic model was used. Tg.AC transgenic mice harbor an activated ras gene under the control of the z-globin promoter (Leder et al., 1990) . As a result of a unique integration arrangement, expression of the activated ras transgene is induced by treatment with TPA, and upon repeated TPA treatment, Tg.AC transgenic mice develop multiple papillomas. These mice serve as a preinitiated model of skin carcinogenesis since DMBA treatment also results in an activating ras mutation (Quintanilla et al., 1986) . Tg.AC transgenic and Tg.AC/K5 E2F1 bigenic mice were treated with TPA for 15 weeks (Figure 1a) . While Tg.AC single transgenic mice developed an average of about eight papillomas per mouse by 15 weeks, the Tg.AC/K5 E2F1 bigenic animals developed less than two papillomas per mouse. This experiment demonstrates that deregulated E2F1 activity can suppress tumor formation at the promotion stage.
In previous experiments, suppression of skin carcinogenesis by E2F1 was examined using only TPA as the tumor promoter. To determine if the inhibition of tumor promotion was specific for TPA, a two-stage carcinogenesis experiment was performed on wild-type and K5 E2F1 transgenic mice using DMBA as the initiator and okadaic acid (OA) as the promoter. OA functions as a tumor promoter by inhibiting protein phosphatase 1 and 2A while TPA stimulates the activity of PKC (Suganuma et al., 1988) . K5 E2F1 transgenic mice (6-week-old) were initiated with 10 nmol of DMBA and promoted for 25 weeks twice weekly with 2 mg of OA ( Figure 1b) . Nontransgenic siblings developed an average of eight papillomas per mouse while the K5 E2F1 transgenic mice developed less than one papilloma per mouse. Thus, E2F1 can suppress tumor promotion by OA, as well as TPA, indicating that E2F1's tumorsuppressive activity is not specific for the type of tumor promoter.
K5 E2F1 transgenic mice are susceptible to UV-induced carcinogenesis
To rule out the possibility that K5 E2F1 transgenic mice have a general epidermal defect that limited their ability to develop skin cancer, we utilized another type of skin carcinogenesis assay. In this experiment, K5 E2F1 transgenic mice and wild-type siblings were repeatedly exposed to ultraviolet B (UVB) radiation for 20 weeks. The transgenic mice developed more skin tumors (both squamous cell carcinomas and papillomas) with shorter latency than the wild-type siblings ( Figure 2 ). This demonstrates that K5 E2F1 transgenic mice are capable of developing skin tumors when subjected to a different type of carcinogenic insult.
One possible explanation for the differential susceptibility of K5 E2F1 transgenic mice to these carcinogens is the difference in mutations resulting from DMBA initiation and UVB carcinogenesis. DMBA causes a mis-sense mutation at codon 61 of the c-Ha-ras gene as the tumor-initiating event (Quintanilla et al., 1986) . If p53 mutations occur at all during two-stage carcinogenesis, they are a late event (Conti, 1994; Yuspa, 1998) . UV carcinogenesis, however, involves early mutation of the p53 gene (Ziegler et al., 1994) . This suggests that differences in the initiating mutation may determine whether E2F1 will suppress or promote tumorigenesis.
Tumor suppression by E2F1 requires p53
Unlike the response to two-stage skin carcinogenesis, K5 E2F1 transgenic mice were highly sensitive to UV carcinogenesis, which involves early mutation of the p53 gene. This suggests that functional p53 may be required for E2F1 to exert its tumor-suppressive activity. To determine if p53 plays a role in the tumor-suppressive activity of E2F1 in this model, a DMBA/TPA skin carcinogenesis experiment was carried out on K5 E2F1 Figure 2 K5 E2F1 transgenic mice are susceptible to UV-induced carcinogenesis. Age-matched female and male K5 E2F1 transgenic and wild-type sibling mice in the SKH1 hairless strain background were irradiated with 100 mJ/cm 2 of UVB three times a week for 15 weeks then UVB-irradiated with 50 mJ/cm 2 three times a week for an additional 5 weeks. The average number of skin tumors per mouse per week in each group is presented. Tumor incidence in wild-type versus K5 E2F1 transgenic mice is significantly different by Poisson regression analysis.
transgenic mice crossed into a p53 À/À background ( Figure 3 ). Nontransgenic and K5 E2F1 transgenic mice either wild type ( þ / þ ) or nullizygous (À/À) for p53 were initiated with 10 nmol of DMBA at 6 weeks of age and promoted twice weekly with 1 mg of TPA as in the other two-stage skin carcinogenesis experiments. As seen in previous experiments, wild-type (nontransgenic, p53 þ / þ ) mice developed multiple papillomas per mouse while K5 E2F1 transgenic mice with functional p53 developed less than one papilloma per mouse. p53 À/À mice without the transgene developed slightly more papillomas than the wild-type mice. Importantly, K5 E2F1 transgenic mice deficient for p53 developed equivalent numbers of papillomas to the wild-type mice. Some mice lacking p53, with or without the E2F1 transgene, had to be removed from the study because of lymphoma development resulting in smaller numbers of mice in these groups. Even with the reduced numbers, the difference in papilloma development between the K5 E2F1 transgenic mice with p53 compared to those without p53 was statistically significant (Po0.001), but there was no significant difference between the wild-type and K5 E2F1 transgenic mice lacking p53 (univariate analysis of variance test, Po0.05). This finding demonstrates that the absence of p53 sensitizes K5 E2F1 transgenic mice to two-stage skin carcinogenesis, highlighting the importance of p53 in E2F1's tumorsuppressive activity.
Inactivation of Arf impairs p53 and p21 induction and leads to hyperplasia in K5 E2F1 transgenic epidermis Increased E2F1 activity can signal to p53 through at least two pathways. One pathway involves the ATM kinase and this pathway has been shown to be important for the apoptotic response to E2F1 overexpression in primary human and mouse fibroblasts (Powers et al., 2004; Rogoff et al., 2004) . The other pathway involves ARF, a transcriptional target of E2F1 and a negative regulator of mdm2. While ARF has been shown by a number of groups to be dispensable for apoptosis induced by E2F1 overexpression or Rb inactivation (Rogoff et al., 2002; Russell et al., 2002; Tolbert et al., 2002; Tsai et al., 2002) , ARF may still be important for mediating other E2F1 activities that are dependent on p53.
Previously, we found that the Arf gene is expressed at relatively high levels in the skin of K5 E2F1 mice, but not in wild-type mice (Wang et al., 2000) . This finding was confirmed by immunohistochemically staining skin sections for the presence of ARF protein.
ARF-positive cells were detected in the epidermis and hair follicles of K5 E2F1 transgenic mice but not wild-type mice (Figure 4a and b) . The specificity of ARF staining was demonstrated by the lack of positive cells in K5 E2F1 transgenic mice that were also null for Arf (Figure 4c) . To determine the effect of Arf inactivation on the induction of p53 by E2F1 in this model, epidermis from K5 E2F1 transgenic mice, with and without ARF, were examined for p53 expression by immunohistochemistry. As expected, K5 E2F1 transgenic mice had an increased number of basal epidermal cells that stained positive for p53 compared to nontransgenic mice (Figures 4d-f and 5a ). In the absence of ARF, the number of p53-positive cells in K5 E2F1 transgenic epidermis was decreased four fold ( Figure 5a ). However, K5 E2F1 transgenic mice lacking ARF still had a three-fold increase in the number of p53-positive epidermal cells compared to wild-type mice. This indicates that the absence of ARF reduces, but does not completely abolish, the response of p53 to deregulated E2F1 activity.
The number of cells expressing the cdk inhibitor p21, a transcriptional target of p53, was also elevated in K5 E2F1 transgenic epidermis compared to wild-type epidermis (Figures 4g-i and 5b ). In the absence of ARF, p21 expression was dramatically decreased in K5 E2F1 transgenic tissue, near the level observed in wildtype epidermis. This further demonstrates that ARF plays a role in signaling from E2F1 to p53 in this model system despite the fact that ARF is not required for the p53-dependent apoptosis observed in K5 E2F1 transgenic epidermis (Russell et al., 2002) .
Previously, we observed that the number of proliferating epidermal cells in K5 E2F1 (line 1.1) transgenic mice was only slightly elevated over the number observed in wild-type mice (Pierce et al., 1998a; Russell et al., 2002) . However, inactivation of Arf resulted in a doubling in the number of proliferating keratinocytes over the number in transgenic mice with functional ARF (Russell et al., 2002) . Consistent with these findings, Arf inactivation cooperated with the K5 E2F1 transgene to induce hyperplasia as measured by epidermal thickness (Figure 5c ). As previously observed (Pierce et al., 1998a) , K5 E2F1 (line 1.1) transgenic epidermis was only modestly thicker than wild-type epidermis. In the absence of ARF, epidermal thickness was significantly increased in K5 E2F1 transgenic mice (Figure 5c ). This suggests that ARF plays an important role in maintaining tissue homeostasis in response to increased E2F1 activity. À/À , 13 K5 E2F1 transgenic and seven K5 E2F1 transgenic p53 À/À mice in the SSIN background were initiated with 10 nmol of DMBA at 6 weeks of age, followed 2 weeks later by twice weekly applications of 1.0 mg of TPA for 20 weeks. Mice were examined weekly for papilloma formation and the average number of papillomas per mouse is plotted.
ARF is important for skin tumor suppression, but not apoptosis, in K5 E2F1 transgenic mice To determine if ARF plays a role in the tumorsuppressive activity of E2F1 in this model, wild-type and K5 E2F1 transgenic mice with and without ARF were subjected to the same two-stage carcinogenesis protocol (Figure 6a ). Consistent with previous experiments, wild-type mice (nontransgenic, Arf þ / þ ) developed an average of eight papillomas per mouse while K5 E2F1 transgenic mice (Arf þ / þ ) were almost completely resistant to papilloma formation. The Arf-null mice (nontransgenic, Arf À/À ) developed more papillomas than their wild-type siblings. Sensitivity to papilloma formation in K5 E2F1 transgenic mice was for the most part restored in the absence of ARF and these mice developed over six papillomas per mouse ( Figure 6a) . As in the p53 null experiment presented above, several Arf null mice, with and without the K5 E2F1 transgene, had to be removed from the study because of lymphoma development unrelated to the transgene. In this experiment, all four genotypes were statistically different from one another where significance is less than 0.05 using the univariate analysis of variance test. This finding demonstrates that ARF is required for E2F1's full tumor-suppressive activity in this model system but that E2F1 has additional, ARF-independent tumor-suppressive activity.
To confirm our previous results that ARF was not required for E2F1-induced apoptosis, mice were initiated with DMBA and treated with TPA twice over a 1-week period. At 24-h after the last TPA treatment, skin samples were taken and stained for the activated form of caspase 3 as an indication of apoptosis. Carcinogen-treated K5 E2F1 transgenic epidermis contained increased numbers of apoptotic cells compared to wild-type mice (Figure 6b ). Inactivation of Arf had no effect on the level of apoptosis observed in K5 E2F1 transgenic epidermis. This result differs somewhat from our previous finding that Arf inactivation actually enhanced apoptosis in K5 E2F1 transgenic mice (Russell et al., 2002) . This difference may be due to the fact that in this experiment mice were treated with DMBA and TPA, whereas our previous data were obtained from untreated mice. Nonetheless, it is clear that while ARF is important for the inhibition of skin carcinogenesis by E2F1, ARF is dispensable for E2F1-induced apoptosis in this model. Thus, these results genetically separate E2F1's ability to induce apoptosis and suppress skin carcinogenesis and suggest that suppression of papilloma formation in K5 E2F1 transgenic mice involves a nonapoptotic mechanism.
Discussion

Suppression of skin carcinogenesis by E2F1
In this study, K5 E2F1 transgenic mice and the twostage skin carcinogenesis model were used to study the tumor-suppressive activity of E2F1. The ability to inhibit two-stage skin carcinogenesis is unique to E2F1 since transgenic expression of related factors, such as Skin tumor suppression by E2F1 requires ARF and p53 JL Russell et al E2F3, E2F4, DP1 or Myc, promotes rather than suppresses skin carcinogenesis (Wang et al., 2000 (Wang et al., , 2001 Rounbehler et al., 2001) . This model system differs from the E2f1 knockout model in that E2F1 is not functioning as a classical tumor suppressor (i.e. its loss is not promoting tumor development). However, this model has some advantages over the E2f1 knockout model for studying the ability of E2F1 to inhibit tumorigenesis. Since it is an 'active' model of tumor suppression, the requirement for downstream effectors, such as ARF and p53, can be assessed. This cannot be performed in the E2f1 knockout model because inactivation of these genes also predispose to tumorigenesis. It is possible that tumor suppression by the endogenous E2f1 gene differs mechanistically from the inhibition of skin carcinogenesis by E2F1 overexpression. Nevertheless, we feel both models are valuable for understanding the tumorsuppressive activity of E2F1 and each may be physiologically relevant in some settings. Increased levels of E2F1 can be caused by mitogenic stimulation (Johnson et al., 1994b) , DNA damage (Blattner et al., 1999; , Rb inactivation (Powers et al., 2004) , and gene amplification (Saito et al., 1995; Gorgoulis et al., 2002) . Using Tg.AC mice as a preinitiated model of multistage carcinogenesis, it was found that transgenic expression of E2F1 inhibited tumor development at À/À mice in the SSIN background were initiated with 10 nmol of DMBA at 6 weeks of age. After 3 and 6 days, the mice were treated with 1 mg of TPA. Skin sections were taken and immunohistochemically stained for activated caspase 3 to identify apoptotic cells. Slides were examined microscopically and the average number of caspase 3-positive cells per 10 mm of epidermis is presented. the promotion stage. Inhibition of tumor promotion was not specific for TPA since E2F1 also inhibited tumor promotion by OA. However, transgenic expression of E2F1 did not suppress UV carcinogenesis but instead enhanced tumor development in response to UV. Unlike the two-stage and Tg.AC models, which involve activated ras as the initiation event, UV carcinogenesis is associated with very early mutations in p53. This indicates that the nature of the initiation event might determine whether E2F1 overexpression will suppress or enhance tumorigenesis. Given that E2F1 can induce p53 activity through multiple pathways, the possibility that p53 might be involved in tumor suppression by E2F1 was tested. Inactivation of p53 in K5 E2F1 transgenic mice restored susceptibility to two-stage carcinogenesis and allowed papilloma formation. This demonstrates that functional p53 is required for E2F1 to exert its tumor-suppressive activity in this model system.
Previous studies using p53 null mice in multistage skin carcinogenesis experiments found that the absence of p53 had the paradoxical effect of reducing papilloma formation while increasing malignant conversion (Kemp et al., 1993; Greenhalgh et al., 1996) . In contrast to those results, we found that p53 null mice had increased numbers of papillomas compared to wild-type mice in response to two-stage skin carcinogenesis. The most likely explanation for this difference is strain background. In our experiments, mice were backcrossed into the SSIN strain, a strain specifically developed for skin carcinogenesis studies (Fischer et al., 1987) . Others have used genetic backgrounds that are a mix between 129 and NIH strains (Kemp et al., 1993) or 129, C57BL/6 and ICR strains (Greenhalgh et al., 1996) .
Like inactivation of p53, inactivation of Arf sensitized K5 E2F1 transgenic mice to two-stage skin carcinogenesis. However, it should be noted that papilloma formation in both p53 and Arf null mice was somewhat reduced by the presence of the K5 E2F1 transgene. Thus, E2F1 has additional tumor-suppressive activity that is not dependent on ARF and p53. Nonetheless, it is clear that both ARF and p53 are necessary for E2F1's full tumor-suppressive activity in this model system.
The fact that ARF is important for suppression of skin carcinogenesis in K5 E2F1 transgenic mice is significant because ARF has been shown to be dispensable for E2F1-induced apoptosis in this same model (Russell et al., 2002) . ARF is also dispensable for p53-dependent apoptosis in response to E2F1 overexpression or Rb inactivation in several other model systems (Rogoff et al., 2002; Tolbert et al., 2002; Tsai et al., 2002) . The ability to genetically separate E2F1-mediated tumor suppression from E2F1-induced apoptosis implies that E2F1 suppresses skin carcinogenesis through a nonapoptotic mechanism.
Interestingly, there is also experimental evidence to suggest that the endogenous E2f1 gene suppresses tumorigenesis through a nonapoptotic mechanism. When transgenic mice expressing Myc under the control of the K5 promoter were crossed into an E2f1 null background, there was an acceleration of tumor development . This acceleration of tumorigenesis in the absence of E2F1 was not associated with a decrease in apoptosis, as might be expected, but rather with an increase in apoptosis in both transgenic epidermis and in skin papillomas. The finding that E2f1 inactivation does not impair Myc-induced apoptosis in this model means that the absence of E2F1 must cooperate with Myc overexpression through a different mechanism to promote tumorigenesis.
ARF functions to maintain tissue homeostasis in response to increased E2F1 activity We find that the absence of ARF cooperates with E2F1 overexpression to induce epidermal hyperplasia (Figure 5c ). This is consistent with our previous findings that epidermal proliferation is increased in K5 E2F1 transgenic epidermis by the inactivation of Arf (Russell et al., 2002) . E2F1-induced apoptosis in untreated transgenic epidermis is also increased by Arf inactivation (Russell et al., 2002) , but apparently this is not sufficient to offset the increased proliferation and prevent hyperplasia. From these findings and similar findings by others, it is now clear that ARF plays an important role in inhibiting E2F1 activity. Since the Arf gene is a transcriptional target of E2F1, this means that E2F1 and ARF regulate each other in a feedback loop that helps to maintain tissue homeostasis.
Previous studies demonstrate that ARF can inhibit E2F1 activity through at least two mechanisms. One mechanism involves direct targeting of E2F1 by ARF. ARF physically interacts with E2F1 and this correlates with an inhibition of E2F1 transcriptional activity that may involve sumoylation of E2F1 (Eymin et al., 2001; Martelli et al., 2001; Rizos et al., 2005) . The other mechanism by which ARF can inhibit E2F1 activity is through the p53-p21-Rb pathway. We show that the increased expression of p53 and p21 in K5 E2F1 transgenic epidermis is impaired in the absence of ARF (Figures 4 and 5) . Upregulation of p21 should lead to an inhibition of cyclin-associated kinase activity and hypophosphorylation of Rb, which would in turn lead to inhibition of E2F1, as well as other E2Fs, by Rb. It is quite possible that activation of this ARF-p53-p21 pathway by E2F1 not only helps to maintain tissue homeostasis in K5 E2F1 transgenic mice but also results in their resistance to two-stage skin carcinogenesis.
As previously mentioned, apoptosis does not appear to be the mechanism by which E2F1 suppresses skin carcinogenesis. In addition to apoptosis, another process by which ARF and p53 could potentially suppress tumor development is premature senescence. Constitutive signaling from a number of oncogenes, including ras, can induce premature senescence and this requires an intact ARF-p53 pathway (Kamijo et al., 1997; Serrano et al., 1997; Lin and Lowe, 2001 ). In many cell types, including primary mouse keratinocytes, p21 is also important for the induction of premature senescence (Missero et al., 1996; Paramio et al., 2001 ). E2F1 has also been shown to induce senescence in primary human fibroblasts dependent on functional ARF and p53 (Dimri et al., 2000) . Moreover, it has recently been shown that prolonged transgenic expression of E2F3 in cells of the pituitary gland induces a senescent-like state (Denchi et al., 2005) . Thus, the induction of premature senescence is one possible mechanism by which the E2F1-ARF-p53 pathway could help to maintain tissue homeostasis and suppress skin carcinogenesis.
Another possible mechanism by which activation of the ARF-p53-p21 pathway by E2F1 could maintain tissue homeostasis and suppress skin carcinogenesis is by promoting terminal differentiation. p21 plays an important role in regulating keratinocyte differentiation. Inactivation of p21 has been shown to disrupt the normal differentiation program and enhance the proliferation potential of primary mouse keratinocytes (Missero et al., 1996; Paramio et al., 2001 ). Although we detect no obvious difference in the expression of epidermal differentiation markers in K5 E2F1 transgenic mice, this does not measure the rate of differentiation. It is therefore possible that upregulation of p21 promotes differentiation in transgenic epidermis to maintain homeostasis and that this results in the differentiation of initiated cells that might otherwise go on to form a papilloma. Future experiments will address the role of p21 and the nonapoptotic processes that are responsible for the ARF and p53-dependent suppression of skin carcinogenesis by E2F1.
Materials and methods
Mice
The generation of K5 E2F1 transgenic mice has been described (Pierce et al., 1998a) . Briefly, the transgene contains the bovine keratin 5 promoter (Ramirez et al., 1994) , the rabbit b-globin intron 2, the human E2F1 cDNA and the simian virus 40 polyadenylation signal. K5 E2F1 transgenic mice (line 1.1), Tg.AC transgenic mice (Leder et al., 1990) , Arf þ /À mice (Kamijo et al., 1997) and p53 þ /À mice (Donehower et al., 1992) were backcrossed into the SSIN strain, an inbred strain of SENCAR, for at least five generations. K5 E2F1 transgenic mice were then crossed to Tg.AC transgenic mice to generate wild-type, single transgenic and bigenic mice. K5 E2F1 transgenic mice were also crossed to mice heterozygous for either Arf or p53 to generate K5 E2F1 transgenic mice heterozygous for Arf or p53. F1 transgenic mice heterozygous for Arf or p53 were then crossed to either Arf or p53 heterozygous mice, respectively, to generate K5 E2F1 transgenic and nontransgenic siblings that were either wild type, heterozygous, or nullizygous for either Arf or p53. Siblings were used for comparison in all experiments. All mice in longterm chemical carcinogenesis studies were at least 92% SSIN strain. For UV carcinogenesis experiments, K5 E2F1 transgenic mice (line 1.1) were backcrossed into the SKH1 hairless strain background (Charles River Laboratories, Wilmington, MA, USA) for at least five generations.
ARF, p53 and p21 immunohistochemistry Skin sections were fixed in formalin, paraffin-embedded and sectioned. After deparaffinization and hydration, sections were blocked with 3% H 2 O 2 in water for 10 min and then washed. For p53 immunohistochemistry, antigen retrieval was performed in 10 mM citrate buffer, pH 6.0, for 15 min in a microwave (10 min on high plus 5 min at 50% power) followed by a 20 min cool down. Slides were blocked in 10% goat serum in PBS for 30 min. Slides were then incubated with p53 primary antibody (Novocastra NCL-p53-CM5p, 1:500 dilution) for 1 h at room temperature followed by washing in buffer for 5 min, changing buffer once. For p19 ARF and p21 immunohistochemistry, antigen retrieval was performed in 1.0 mM EDTA buffer, pH 8.0, for 10 min in a microwave followed by a 20 min cool down. Slides were blocked in 10% goat serum for p19 ARF or 10% rabbit serum for p21 diluted in PBS for 30 min. Slides were then incubated with primary p19 ARF polyclonal antibody (Abcam, 1:50 dilution) or p21 monoclonal antibody (Santa Cruz, 1:50) overnight at 41C followed by washing for 5 min, changing buffer once. Detection of p53 and p19 ARF utilized the Dako Envision plus-HRP detection kit with diaminobenzidine (DAB). Detection of p21 used a standard three-step IHC peroxidase system with DAB.
Two-stage skin carcinogenesis assay
The dorsal skin of 6-8-week-old mice in the SSIN strain was shaved 1-2 days before carcinogen treatment. Tumors were initiated by topical application of 10 nmol of DMBA in 200 ml of acetone to the dorsal skin. After 2 weeks, tumors were promoted with twice weekly topical applications of 1.0 mg of TPA or 2 mg of OA in 200 ml of acetone. Mice were scored for palpable papillomas weekly. For the promotion experiment with Tg.AC transgenic mice, mice were treated with 1.0 mg of TPA in 200 ml of acetone applied topically to dorsal epidermis. Mice were treated twice weekly and observed for papilloma development until an end point, defined by tumor load, was reached.
UV carcinogenesis assay
In all, 6-8-week-old K5 E2F1 transgenic mice and wild-type siblings in the SKH1 strain background were UVB-irradiated with 12 Westinghouse FS20 sunlamps in an irradiation chamber that was manufactured to maximize fluence uniformity (Starch Art, Smithville, TX, USA) (Mitchell et al., 1999) . According to the manufacturer's specifications, the broadband range for the UV lamps is between 280 and 400 nm, with 80% of the light in the UVB region, and 20% in the UVA region, with a peak wavelength at 297 nm. The UV light is filtered by transparent plastic that covers the mice in the irradiation chamber to block all UVC wavelengths. The fluence was measured on a rotating platform 20 cm from the dorsal surface of the mice with an IL-1400A Radiometer/ Photometer coupled to an SEL 240/UV-B-1/TD detector containing a 280 nm Sharp Cutoff Filter (International Light, Newburyport, MA, USA). K5 E2F1 transgenic mice and wildtype siblings were UVB-irradiated with 100 mJ/cm 2 three times a week for 15 weeks. Afterwards the mice were treated with only 50 mJ/cm 2 three times a week for an additional 5 weeks. UVB irradiation was terminated after 20 weeks and the mice were monitored for an additional 3 weeks. Mice with tumors greater than 1 cm were euthanized during the study.
Short-term carcinogen treatment
The dorsal skin of all mice was shaved at 6-8 weeks of age 2 days before their first treatment. Wild-type and K5 E2F1 transgenic mice (line 1.1) in the SSIN strain background, including mice null for Arf or p53, were initiated with 10 nmol of DMBA in 200 ml of acetone followed 1 week later with twice weekly topical applications of TPA (1 mg in 200 ml of acetone) over a 1 week period. Mice were killed 24 h after the last treatment and skin sections were frozen in Tissue Freezing Medium from Triangle Biomedical Sciences (#H-TFM).
Activated caspase-3 immunohistochemistry
Cryosections (5 mm) were fixed in 10% neutral buffered formalin for 3 min and then washed. Slides were then placed in 3% H 2 O 2 in water for 10 min at room temperature. After blocking with 10% goat serum in PBS for 30 min, sections were incubated with primary caspase 3 antibody (1:2000, R&D Systems #AF835) for 30 min. Slides were then washed and subjected to standard three-step IHC-peroxidase detection using DAB (BioGenex). Slides were counterstained with hematoxylin for 12-15 s, rinsed and coversliped. Apoptosis was scored as the average number of activated caspase 3-positive cells per 10 mm of interfollicular epidermis.
